BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
News|Articles|September 18, 2026
Beyond the Data: Why Scientific Storytelling Will Define the Future of Medical Communications
Author(s)EVERSANA INTOUCH
Scientific storytelling is becoming a critical differentiator in Medical Affairs. Discover how leading organizations are moving beyond standalone assets and data-heavy communications to create connected scientific narratives, activate modern influence networks, and deliver more meaningful engagement with healthcare professionals.
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Trending on PharmExec
1
The Next Biopharma Revolution: Quantum Computing
2
Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acquires Health Economics Firm Estima Scientific
3
Rebuilding Clinical Data Workflows for the AI Era
4
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
5